Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: Anthony Wong who wrote (6851)	1/28/1999 4:27:00 PM
From: Anthony Wong	Read Replies (2) \| Respond to of 9523

01/28 15:33 Selectus seeks to patent Viagra companion drug WEST CONSHOHOCKEN, Pa., Jan 28 (Reuters) - Selectus Pharmaceuticals said Thursday it had filed a U.S. patent application covering the use of esprolol plus Viagra to allow persons with heart disease to use the popular Pfizer <PFE.N> anti-impotence drug. Privately held Selectus, a development-stage company started in early 1997, said esprolol is a potent, fast-acting beta-blocker that lessens heart rates and blood pressure during physical exertion. To date a number of deaths have been reported allegedly in connection with the use of the anti-impotence drug. Cardiac implications were indicated in some of the deaths, though the U.S. Food and Drug Administration has said there is no proof that Viagra itself caused the deaths. Esprolol is currently undergoing Phase II clinical trials, Selectus said, and the drug was well-tolerated in Phase I trials. The company is looking for a corporate partner to take over the Phase III and IV clinical work and the marketing of esprolol. In addition to use in conjunction with Viagra, the drug could halt angina, panic attacks, the cardiovascular affects of acute anxiety, and migraine headaches, it said.